Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

(2022) Li Li et al.   Communications Biology

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma

(2022) Atakan Topcu et al.   Bosnian Journal of Basic Medical Sciences

Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates

(2021) Florian Simon et al.   PHARMACEUTICAL RESEARCH

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

(2020) David Balakirouchenane et al.   Cancers

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

(2020) S. Park et al.   ANNALS OF ONCOLOGY

Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients

(2020) Evelina Cardoso et al.   CLINICAL THERAPEUTICS

Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail

(2020) Camille Lenoir et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

(2020) Arthur Geraud et al.   Cancers

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

(2019) Stéphanie van Hoppe et al.   PHARMACOLOGICAL RESEARCH

The Evolving Landscape of Resistance to Osimertinib

(2019) Adam J. Schoenfeld et al.   Journal of Thoracic Oncology

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer

(2019) Keiko Nakao et al.   Scientific Reports

Overview of current systemic management of EGFR-mutant NSCLC

(2018) W -H Hsu et al.   ANNALS OF ONCOLOGY

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

(2018) Karthick Vishwanathan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy

(2018) A. Kenneth MacLeod et al.   CLINICAL CANCER RESEARCH

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?

(2018) Sabrina Rossi et al.   Future Oncology

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

(2018) Nicolas Girard   Future Oncology

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients

(2018) Rafael Reis et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?

(2018) Chor-Kuan Lim et al.   EUROPEAN JOURNAL OF CANCER

Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer

(2018) Yijun Jia et al.   LUNG CANCER

Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer

(2017) Antonio Rossi et al.   Expert Opinion on Drug Metabolism & Toxicology

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers

(2017) Karthick Vishwanathan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

(2017) Monique B. Nilsson et al.   Science Translational Medicine

Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials

(2016) J. C.-H. Yang et al.   ANNALS OF ONCOLOGY

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

(2016) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old

(2016) Frederic Bigot et al.   INVESTIGATIONAL NEW DRUGS

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

(2015) D. Planchard et al.   ANNALS OF ONCOLOGY

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

(2015) Djoeke de Wit et al.   DRUG DISCOVERY TODAY

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erlotinib

(2015) Emilie Petit-Jean et al.   THERAPEUTIC DRUG MONITORING

High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib

(2015) Ondrej Fiala et al.   TUMOR BIOLOGY

Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer

(2013) Masahide Fukudo et al.   CLINICAL PHARMACOKINETICS

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma

(2012) Olivier Mir et al.   PLoS One

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

(2009) Fabienne Thomas et al.   EUROPEAN JOURNAL OF CANCER